XEL
57
4
AVGO
25
-2
WMB
52
-3
NEE
47
-3
AMAT
49
-3
XOM
62
3
MOS
42
6
VTR
57
-3
BAC
50
-7
AES
41
-2
MDLZ
48
-2
TXN
40
-2
SRE
38
-4
HST
62
23
MCO
74
3
FFIV
58
3
HAS
46
3
ROK
47
4
UHS
66
12
AME
50
2
XEL
57
4
AVGO
25
-2
WMB
52
-3
NEE
47
-3
AMAT
49
-3
XOM
62
3
MOS
42
6
VTR
57
-3
BAC
50
-7
AES
41
-2
MDLZ
48
-2
TXN
40
-2
SRE
38
-4
HST
62
23
MCO
74
3
FFIV
58
3
HAS
46
3
ROK
47
4
UHS
66
12
AME
50
2
Financhill
Back

Apellis Pharmaceuticals 10K Form

Sell
34

APLS
Apellis Pharmaceuticals

Last Price:
39.81
Seasonality Move:
-5.11%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $396.59M
Cash Flow: $-133.28M
Price / Cash Flow: 0
Annual Sales: $2.20
Price / Book: 17.69

Profitability

EPS (TTM): -3.46000
Net Income (TTM): $-417.27M
Gross Margin: $338.08M
Return on Equity: -143.79%
Return on Assets: -48.15%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 6 years for APLS is 85.25%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 126.28% of Gross Profit Margin.
  • The Research & Development expenses have been 89.36% of Revenue.
  • The Interest Expense is -5.60% of Operating Income.
  • The Net Earning history of APLS is -133.29% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 0.35
Current Ratio: 3.77
Quick Ratio: 2.78

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 37.18

APLS Technical Analysis vs Fundamental Analysis

Sell
34
Apellis Pharmaceuticals (APLS) is a Sell

Is Apellis Pharmaceuticals a Buy or a Sell?